These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27537387)

  • 1. HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
    Ørbo A; Arnes M; Lyså LM; Borgfeldt C; Straume B
    Br J Cancer; 2016 Sep; 115(6):725-30. PubMed ID: 27537387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Kaino T; Sager G; Ørbo A;
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study.
    Barr CE; Sergeant JC; Agnew HJ; Bolton J; McVey RJ; Crosbie EJ
    BJOG; 2023 Jul; 130(8):941-948. PubMed ID: 36715558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
    Orbo A; Vereide A; Arnes M; Pettersen I; Straume B
    BJOG; 2014 Mar; 121(4):477-86. PubMed ID: 24286192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
    Ørbo A; Arnes M; Lyså LM; Straume B
    Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
    Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
    Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
    Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
    Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of diagnostic accuracy between endometrial curettage and pipelle aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group Study (KGOG 2019).
    Kim MK; Seong SJ; Lee TS; Ki KD; Lim MC; Kim YH; Kim K; Joo WD
    Jpn J Clin Oncol; 2015 Oct; 45(10):980-2. PubMed ID: 26206899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
    Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
    Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
    Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
    Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
    Orbo A; Arnes M; Pettersen I; Larsen K; Hanssen K; Moe B
    Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrauterine Progestin Therapy as a New Approach to Premalignant Endometrial Polyps: A Prospective Observational Study.
    Sletten ET; Arnes M; Vereide AB; Ørbo A
    Anticancer Res; 2019 Sep; 39(9):4897-4903. PubMed ID: 31519593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
    Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
    Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
    Gallos ID; Devey J; Ganesan R; Gupta JK
    Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
    Emarh M
    Arch Gynecol Obstet; 2015 Dec; 292(6):1339-43. PubMed ID: 26015309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study.
    Sletten ET; Arnes M; Lyså LM; Larsen M; Ørbo A
    BJOG; 2019 Jun; 126(7):936-943. PubMed ID: 30548528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
    Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
    Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.